Loading...

Guardant Health, Inc.

GHNASDAQ
Healthcare
Medical - Diagnostics & Research
$50.50
$0.32(0.64%)

Guardant Health, Inc. GH Peers

See (GH) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
GH$50.50+0.64%6.3B-14.90-$3.39N/A
DHR-PB$1,261.26-0.78%916.8B146.01$8.64+0.58%
TMO$429.33+0.37%162.1B25.17$17.06+0.38%
DHR$203.20+0.35%145.4B39.30$5.17+0.58%
IDXX$547.01+0.79%44B50.60$10.81N/A
A$121.38+0.60%34.5B29.90$4.06+0.81%
IQV$164.24-0.25%28.4B22.41$7.33N/A
MTD$1,209.08+0.28%25.1B30.20$40.04N/A
NTRA$161.76+0.12%22.1B-109.30-$1.48N/A
WAT$350.22-0.48%20.8B31.75$11.03N/A
Showing 1 to 10 of 89 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

GH vs DHR-PB Comparison

GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GH stands at 6.3B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GH is priced at $50.50, while DHR-PB trades at $1,261.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GH currently has a P/E ratio of -14.90, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GH's ROE is +3.69%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for GH.

Stock Price Comparison

Loading...

Frequently Asked Questions

;